Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer
收藏NIAID Data Ecosystem2026-03-08 收录
官方服务：
资源简介：
This is a Phase 2, open-label, randomized, 3-arm trial investigating the efficacy of two Sym004 doses (Arm A and Arm B) compared with a control group (Arm C) in subjects with metastatic colorectal cancer (mCRC) and acquired resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs).
创建时间：
2014-03-15
